Longitudinal Early-onset Alzheimers Disease Study (LEADS) (Alzheimer's Subjects)
Longitudinal Early-Onset Alzheimers Disease Study (LEADS) (Alzheimer's Subjects)
Sponsor: National Institute on Aging NIH DHHS
Enrolling: Male and Female Patients
IRB Number: AAAR8180
U.S. Govt. ID: NCT03507257
Contact: Arlene Mejia: 212-305-9168 / am4717@cumc.columbia.edu
Additional Study Information: The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment . Clinical/cognitive, imaging, biomarker, and genetic characteristics will be assessed across two cohorts: early onset Alzheimer's Disease (EOAD) participants and cognitively normal (CN) control participants. Early-onset Alzheimer's disease (EOAD) affects about 5% of individuals with Alzheimer's disease (AD) (~200,000-300,000 cases in the United States). The Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) explores the development of EOAD and how it compares to the more common late-onset form of AD. To successfully move toward effective treatments, researchers need to understand the genetic, biological and clinical processes involved in EOAD. This study involves memory testing, blood and CSF collection, MRI and PET scans. Your participation in LEADS could contribute to future medical advances to help all those affected by AD.
This study is closed
Lawrence Honig, MD, PhD
Do You Qualify?
Are you between the ages of 40-64 (inclusive)? Yes No
Do you have a study partner who spends a minimum of 10 hours per week with you and who is generally aware of your activities? Yes No
Are you cognitively impaired? (Early Onset Alzheimer's Disease or Early Onset non-Alzheimer's Disease)) Yes No
Will you complete MRI and PET Scans? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Arlene Mejia